This initial NeuroCAST series is devoted to a discussion about the formation of neutralizing antibodies in interferon beta-treated individuals with multiple sclerosis. The information is divided into five modules, or sessions:
- Multiple Sclerosis Treatment Decisions
- The molecular biology of beta-interferon
- Incidence and biological significance of NAbs to beta-1a (data from the Avonex® trial)
- Clinical management and the role of NAbs
- New developments in NAb literature
- NAbs Review
